Matchpoint Therapeutics is a biotechnology company that integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses.
Matchpoint Therapeutics has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.
Matchpoint Therapeutics's investors include Digitalis Ventures, Atlas Venture, Alexandria Venture Investments, Sanofi Ventures, Vertex Ventures HC.
Matchpoint Therapeutics is headquartered in Cambridge, United States.
Matchpoint Therapeutics is a biotechnology company that integrates chemoproteomics, ML, and covalent chemistry to treat serious illnesses.
Matchpoint Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Matchpoint Therapeutics — Funding & Investors." VCBacked, October 14, 2022, https://www.vcbacked.co/company/matchpoint-therapeutics. Accessed July 20, 2026.
VCBacked. (2022). Matchpoint Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/matchpoint-therapeutics
{{cite web |title=Matchpoint Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/matchpoint-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated